H.C. Wainwright Lifts PT on Summit Therapeutics (SMMT) to $50 From $44

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best strong buy growth stocks to buy now. On August 27, H.C. Wainwright raised the firm’s price target on Summit Therapeutics Inc. (NASDAQ:SMMT) to $50 from $44, keeping a Buy rating on the shares.

The firm told investors in a research note that Akeso’s HARMONi-A study for ivonescimab validates the China data, showing that ivonescimab beats Keytruda.

It added that it is time to own shares of Summit Therapeutics Inc. (NASDAQ:SMMT), as it holds the position of Akeso’s partner in the United States.

Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company that discovers, develops, and commercializes patient, caregiver, physician, and societal-friendly medicinal therapies that target serious unmet medical needs, extend life, and enhance life quality. The company’s clinical programs focus on Clostridioides Difficile Infection (CDI).

While we acknowledge the potential of SMMT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.